ES2618353T3 - Clasificación de tumores y pronóstico del cáncer de mama - Google Patents

Clasificación de tumores y pronóstico del cáncer de mama Download PDF

Info

Publication number
ES2618353T3
ES2618353T3 ES08872935T ES08872935T ES2618353T3 ES 2618353 T3 ES2618353 T3 ES 2618353T3 ES 08872935 T ES08872935 T ES 08872935T ES 08872935 T ES08872935 T ES 08872935T ES 2618353 T3 ES2618353 T3 ES 2618353T3
Authority
ES
Spain
Prior art keywords
ratio
subject
index
classified
cut
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08872935T
Other languages
English (en)
Spanish (es)
Inventor
Mark G. Erlander
Xiao-Jun Ma
Dennis Sgroi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotheranostics Inc
Original Assignee
Biotheranostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotheranostics Inc filed Critical Biotheranostics Inc
Application granted granted Critical
Publication of ES2618353T3 publication Critical patent/ES2618353T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES08872935T 2007-09-06 2008-09-06 Clasificación de tumores y pronóstico del cáncer de mama Active ES2618353T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97052907P 2007-09-06 2007-09-06
PCT/US2008/075528 WO2009108215A1 (en) 2007-09-06 2008-09-06 Tumor grading and cancer prognosis

Publications (1)

Publication Number Publication Date
ES2618353T3 true ES2618353T3 (es) 2017-06-21

Family

ID=40790735

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08872935T Active ES2618353T3 (es) 2007-09-06 2008-09-06 Clasificación de tumores y pronóstico del cáncer de mama

Country Status (7)

Country Link
US (3) US9447470B2 (enExample)
EP (1) EP2195467B1 (enExample)
JP (2) JP2010538609A (enExample)
CN (1) CN102395682B (enExample)
CA (1) CA2698569A1 (enExample)
ES (1) ES2618353T3 (enExample)
WO (1) WO2009108215A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
DK1899484T3 (da) * 2005-06-03 2015-11-23 Biotheranostics Inc Identifikation af tumorer og væv
WO2010151731A1 (en) * 2009-06-26 2010-12-29 University Of Utah Research Foundation Materials and methods for the identification of drug-resistant cancers and treatment of same
EP2648762B1 (en) * 2010-12-09 2018-02-21 Biotheranostics, Inc. Post-treatment breast cancer prognosis
US20120271553A1 (en) * 2011-04-22 2012-10-25 Ge Global Research Analyzing the expression of biomarkers in cells with clusters
US9470693B2 (en) 2012-05-18 2016-10-18 University Of North Dakota Method for quantifying proteins and isoforms thereof
IN2014MN02418A (enExample) * 2012-05-22 2015-08-14 Nanostring Technologies Inc
WO2013190081A1 (en) * 2012-06-22 2013-12-27 Proyecto De Biomedicina Cima, S.L. Methods and reagents for the prognosis of cancer
AU2014317843A1 (en) * 2013-09-09 2016-03-24 British Columbia Cancer Agency Branch Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy
WO2015038682A1 (en) * 2013-09-11 2015-03-19 bio Theranostics, Inc. Predicting breast cancer recurrence
US10253369B2 (en) 2014-05-29 2019-04-09 Biotheranostics, Inc. Predicting likelihood of response to combination therapy
MX2018005867A (es) 2015-11-13 2018-09-21 Biotheranostics Inc Integracion de las caracteristicas tumorales con el indice de cancer de mama.
CN107119055A (zh) * 2017-05-18 2017-09-01 南京中医药大学 分子标志物bub1b基因及其应用
CN110021433B (zh) * 2017-08-30 2023-11-17 中山大学 一种用于精准预测胃肠胰神经内分泌肿瘤患者预后的系统
CN113490850B (zh) * 2018-08-17 2024-12-06 基因泰克公司 用于治疗乳腺癌的诊断和治疗方法
CN109706160A (zh) * 2019-02-22 2019-05-03 广西医科大学 重组人蛋白激酶Nek2蛋白表达和纯化方法
KR102405973B1 (ko) * 2019-09-20 2022-06-07 고려대학교 산학협력단 유방암 초음파 영상과 유전자 정보를 이용한 유방암 치료법 선택을 위한 정보를 제공하는 방법
KR102508210B1 (ko) * 2020-10-16 2023-03-10 고려대학교 산학협력단 유방암 초음파 영상을 이용한 dna 유전자 정보를 제공하는 방법
CN115029437A (zh) * 2022-04-28 2022-09-09 深圳市陆为生物技术有限公司 检测样本中生物标志物的试剂在制备乳腺癌患者化疗响应评估产品中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
WO2000029044A2 (en) 1998-11-13 2000-05-25 Pro Duct Health, Inc. Devices and methods to identify ductal orifices during nipple aspiration
US20030228575A1 (en) * 2001-01-31 2003-12-11 Yuk Ming Dennis Lo Combination of circulating epstein-barr virus (EBV) DNA in the serum or plasma of patients and a method to assess EBV subtypes for the prediction and detection of epstein-barr virus associated cancers
US20030064385A1 (en) * 2001-05-16 2003-04-03 Dressman Marlene Michelle Genes expressed in breast cancer as prognostic and therapeutic targets
US20030138793A1 (en) * 2001-06-10 2003-07-24 Irm Llc, A Delaware Limited Liability Company Molecular signatures of commonly fatal carcinomas
US20030198972A1 (en) * 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
WO2005039382A2 (en) * 2003-06-24 2005-05-06 Genomic Health Prediction of likelihood of cancer recurrence
EP1644858B1 (en) * 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
BRPI0414446A (pt) * 2003-09-18 2006-11-14 Genmab As métodos para triar um agente terapêutico, para a supressão da sequência de polinucleotìdeo, para o tratamento de um cáncer não dependente de esteróide, para triar a ligação de um agente especificamente a um polinucleotìdeo e para determinar se um paciente está em risco de desenvolver ou ter um cáncer não dependente de esteróide, composição farmacêutica, usos de um agente terapêutico, de uma molécula anti-sentido ou de uma célula que expressa e/ou contém a molécula anti-sentido, de pelo menos uma das proteìnas de membrana imunogênicas, fragmentos, derivados ou homólogos destas ou de uma célula que contém e/ou que expressa pelo menos uma das proteìnas de membranas imunogênicas ou fragmentos, derivados ou homólogos destas e de um agente ou anticorpo, agente, e, kit para identificar um paciente em risco de desenvolver ou ter cáncer não dependente de esteróide
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
CA2539107A1 (en) 2003-09-19 2005-03-31 Arcturus Bioscience, Inc. Predicting breast cancer treatment outcome
US7504214B2 (en) 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer
US7498693B2 (en) 2004-02-18 2009-03-03 Diversified Technologies, Inc. More compact and higher reliability power source system
CA2608643A1 (en) * 2005-05-13 2006-11-16 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
DK1899484T3 (da) * 2005-06-03 2015-11-23 Biotheranostics Inc Identifikation af tumorer og væv

Also Published As

Publication number Publication date
JP2015057055A (ja) 2015-03-26
JP2010538609A (ja) 2010-12-16
EP2195467A1 (en) 2010-06-16
US20180291461A1 (en) 2018-10-11
CN102395682B (zh) 2015-09-30
US9447470B2 (en) 2016-09-20
US20210371934A1 (en) 2021-12-02
US12492432B2 (en) 2025-12-09
EP2195467B1 (en) 2016-12-14
US20110136680A1 (en) 2011-06-09
WO2009108215A1 (en) 2009-09-03
CN102395682A (zh) 2012-03-28
CA2698569A1 (en) 2009-09-03
US11021754B2 (en) 2021-06-01

Similar Documents

Publication Publication Date Title
ES2618353T3 (es) Clasificación de tumores y pronóstico del cáncer de mama
Grover et al. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research
Wreesmann et al. Influence of extracapsular nodal spread extent on prognosis of oral squamous cell carcinoma
Zhao et al. Combining multidimensional genomic measurements for predicting cancer prognosis: observations from TCGA
Budczies et al. Classical pathology and mutational load of breast cancer–integration of two worlds
Lowes et al. Circulating tumor cells and implications of the epithelial-to-mesenchymal transition
Chen et al. Development and validation of a nomogram for predicting survival in male patients with breast cancer
Kanemasa et al. Beta‐2 microglobulin as a significant prognostic factor and a new risk model for patients with diffuse large B‐cell lymphoma
Passoni et al. Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis
SG10201804276UA (en) Triaging of patients having asymptomatic hematuria using genotypic and phenotypic biomarkers
MX374827B (es) Metodo in vitro para prognosis y para diseñar una terapia personalizada para un sujeto que padece cancer.
EA035451B9 (ru) Способ диагностики рака с использованием геномного секвенирования
Ebrahimi et al. The prognosis of N2b and N2c lymph node disease in oral squamous cell carcinoma is determined by the number of metastatic lymph nodes rather than laterality: evidence to support a revision of the American Joint Committee on Cancer staging system
NZ719474A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
GB2427468A (en) Devices and methods for enrichment and alteration of circulating tumour cells and other particles
Xu et al. The association of HOTAIR with the diagnosis and prognosis of gastric cancer and its effect on the proliferation of gastric cancer cells
Mazzola et al. Recent BRCAPRO upgrades significantly improve calibration
Qi et al. Pre-treatment Glasgow prognostic score and modified Glasgow prognostic score may be potential prognostic biomarkers in urological cancers: a systematic review and meta-analysis
EP2558865A4 (en) METHOD AND KIT FOR CANCER DIAGNOSIS
Granit et al. Axes of differentiation in breast cancer: untangling stemness, lineage identity, and the epithelial to mesenchymal transition
MY195697A (en) Method of Prognosing and Predicting Breast Cancer Recurrence, Markers Employed Therein and Kit Thereof
Ball et al. Lymph node density predicts recurrence and death after inguinal lymph node dissection for penile cancer
Zhang et al. Identification of a recurrence signature and validation of cell infiltration level of thyroid cancer microenvironment
CN107561280B (zh) 一种预测乳腺癌复发的试剂盒
Jiang et al. Overexpression of LncRNA GHET1 predicts an unfavourable survival and clinical parameters of patients in various cancers